Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Thyroid Carcinoma, Anaplastic 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

trametinib 8dabrafenib 7pembrolizumab 5Paclitaxel 5lenvatinib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3fosbretabulin 2cobimetinib 2cemiplimab 2atezolizumab 2Vemurafenib 2Sorafenib 2Nivolumab 2Bevacizumab 2zimberelimab 1tremelimumab 1selpercatinib 1sapanisertib 1sacituzumab govitecan 1pegfilgrastim 1fludarabine 1efatutazone 1durvalumab 1ceritinib 1cabozantinib 1aldesleukin 1abemaciclib 1Thyroidectomy 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid Carcinoma, Anaplastic × ceritinib × Clear all
NCT02289144 2019-07-30

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡